Scarica l'app Stockscreener
2.95
8.46%
0.23
Dare Bioscience Inc Borsa (DARE) Ultime notizie
Daré Bioscience Rebalances Classified Board Structure and Terms - TipRanks
Daré Bioscience (DARE) reclassifies director to rebalance staggered board - Stock Titan
Daré Bioscience (NASDAQ: DARE) asks shareholders to approve 1.5M plan shares, vote June 11 - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
DARE Technical Analysis | Trend, Signals & Chart Patterns | DARE BIOSCIENCE INC (NASDAQ:DARE) - ChartMill
DARÉ BIOSCIENCE, INC. Files Form 8-K Report with SEC for Unregistered Sales of Equity Securities – April 2026 - Minichart
Dare Bioscience completes closing of Regulation A equity offering By Investing.com - Investing.com South Africa
Dare Bioscience completes closing of Regulation A equity offering - Investing.com
Daré Bioscience Completes Regulation A Preferred Stock Offering - TipRanks
Daré Bioscience (NASDAQ: DARE) closes Regulation A sale of 3,470 units - Stock Titan
Maxim Group Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $8 - Moomoo
LEXX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Head-To-Head Review: Dare Bioscience (NASDAQ:DARE) & Appili Therapeutics (OTCMKTS:APLIF) - Defense World
Maxim Group Upgrades Daré Bioscience (DARE) - MSN
Dare Bioscience, Inc. (DARE) reports Q4 loss, lags revenue estimates - MSN
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update - manilatimes.net
Dare Bioscience Q4 2025 Earnings Call Transcript - MarketBeat
Transcript : Daré Bioscience, Inc., 2025 Earnings Call, Mar 26, 2026 - marketscreener.com
Dare Bioscience, Inc. (DARE) Announces Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
Dare Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
Earnings call transcript: Daré Bioscience Q4 2025 highlights capital efficiency By Investing.com - Investing.com India
Earnings call transcript: Daré Bioscience Q4 2025 highlights capital efficiency - Investing.com
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Daré Bioscience, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:DARE) 2026-03-26 - Seeking Alpha
Q4 2025 Dare Bioscience Inc Earnings Call Transcript - GuruFocus
Daré Bioscience (NASDAQ: DARE) expands dual-path women’s health model - Stock Titan
Daré Bioscience (NASDAQ: DARE) details 2025 loss, funding boost and upcoming product launches - stocktitan.net
Dare Bioscience FY 2025 earnings preview - MSN
Dare Bioscience Inc (DARE) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
Daré outlines expanded dual path strategy targeting $4.5B hormone therapy market while accelerating commercialization in Q4 2025 - MSN
Daré Bioscience, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Dare Bioscience Inc expected to post a loss of 43 cents a shareEarnings Preview - TradingView
A Viagra ingredient is now in a topical cream developed for women - Stock Titan
On National Viagra Day, Women Finally Claim Their Turn: - ChartMill
Dare Bioscience (DARE) Expected to Announce Earnings on Monday - Defense World
Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026 - The Manila Times
Daré Bioscience, Inc. to Host Conference Call on March 26, 2026, for Year-End Financial Results and Company Update - Quiver Quantitative
Daré Bioscience schedules March 26 webcast for 2025 results - stocktitan.net
DARE BIOSCIENCE, INC. Files Form 8-K with SEC Reporting Unregistered Sale of Equity Securities - Minichart
Dare Bioscience secures NIH funding extension for preterm birth therapy - MSN
Daré Bioscience (DARE) issues 43,050 preferred-and-warrant units - Stock Titan
Daré Bioscience extends NIH grant period for preterm birth drug By Investing.com - Investing.com Australia
DARE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Dare Bioscience (DARE) Advances Investigational Preterm Birth Tr - GuruFocus
Dare Bioscience receives NIH funding extension for preterm birth treatment By Investing.com - Investing.com Australia
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth - manilatimes.net
NIH funds hormone ring as preterm birth lacks FDA-approved treatment - Stock Titan
Daré Bioscience Participates in Virtual Investor “What This Means” Segment - Sahm
Dare Bioscience Participates in Virtual Investor "What This Means" Segment - Bitget
Persistent HPV has no FDA-approved drug; Daré CEO lays out DARE-HPV trial plan - Stock Titan
2.19%
0.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):